-
Mashup Score: 1Management of relapsed/refractory mantle cell lymphoma - 13 day(s) ago
In this review we summarize the current evidence describing the management of patients with relapsed/refractory MCL and outline the various novel therapeutics that have been developed over the past…
Source: www.tandfonline.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 1Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population - PubMed - 9 month(s) ago
Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable outcomes achieved with immunochemotherapy. However, outcomes of gene expression profiling (GEP)-defined molecular subgroups in a real-world DLBCL population remain unknown. Here we examined the prevalence and out …
Source: pubmed.ncbi.nlm.nih.govCategories: Hematologists1, Latest HeadlinesTweet-
https://t.co/PzDifpMFuu 1️⃣ Amazing work from the group in Vancouver lead by David Scott and Waleed Alduaij Reclassification is needed based on these new data
-
-
Mashup Score: 0Authorship: why not just toss a coin? - 11 month(s) ago
Journal List Am J Physiol Cell Physiol PMC2544445 Am J Physiol Cell Physiol. 2008 Sep; 295(3): C567–C575. if you are reading this commentary, the title…
Source: PubMed Central (PMC)Categories: Hematologists1, Latest HeadlinesTweet-
@AaronGoodman33 There is big misconceptions about authorship even among “academics” Worst type of unethical authorship is “coercive authorship” when seniors exert their seniority over junior researchers!Using intimidation, relationships and publish or perish tactics. See: https://t.co/mBd9ioZNdm
-
-
Mashup Score: 1Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP - PubMed - 1 year(s) ago
Consolidative radiation therapy (RT) for advanced-stage diffuse large B-cell lymphoma (DLBCL) remains controversial, with routine practice continuing to include RT in patients with initial bulky disease or residual masses. Positron emission tomography (PET)-computed tomography is a sensitive modalit …
Source: PubMedCategories: Hematologists1, Latest HeadlinesTweet-
@AaronGoodman33 @jryckman3 @SprakerMDPhD If PET adapted approach was used and end of treatment was a complete metabolic response then I wouldn’t radiate. https://t.co/TdnM8GMJ75
-
-
Mashup Score: 0
Key Points. Clinical and biological features of therapy-related and de novo NPM1-mutated AML overlap.Therapy-related NPM1-mutated AML most likely represents a d
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet-
#AML #hematology Therapy related NPM1 AML probably doesn’t exist. All NPM1 AML are likely represent a de novo disease and if it happens after therapy then it is just a coincidence! Interesting! https://t.co/ptjH2o2v1h
-
-
Mashup Score: 1
A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
Source: medicalxpress.comCategories: Hematologists1, Latest HeadlinesTweet-
RT @np_grwl: https://t.co/msLwv2GtCA #revumenib #resistance. "They're driven by a rearrangement of the #MLL1 gene or a mutation in the NPM1…
-
-
Mashup Score: 0Claims under scientific scrutiny Part1: Lecture# 2 - 1 year(s) agoSource: YouTubeCategories: Hematologists1, Latest HeadlinesTweet
-
@Faisal_Alsayegh If you have a chance to watch this video? I have talked about all kinds of logics in a series of lectures I hope you find them useful 🙏 https://t.co/ktOvDxB41D
-
-
Mashup Score: 0What to Do When Patients Don't Listen - 1 year(s) ago
You do all you can for your patients, so when they’re nonadherent, it can be frustrating. What can you do when patients don’t listen?
Source: MedscapeCategories: Hematologists1, Latest HeadlinesTweet-
Many people don’t know the difference between a “noncompliant patient” and a “nonadherent patient” Here is a very important article addressing these. https://t.co/NiuHV8Oi7q
-
-
Mashup Score: 8TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype - 1 year(s) ago
Key Points. Not applicableNot applicable
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet-
RT @TalhaBadarMD: TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype https://t.co/13sqfrvRNH ➡️ No diff…
-
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Source: New England Journal of MedicineCategories: Hematologists1, Latest HeadlinesTweet-
https://t.co/YKR0LUlnf7 Today’s journal club’ article @KSUMCIM We discussed the use of bayesian vs frequentist inference of data!
-
https://t.co/Bm39o6pmpU